Cover Image

177Lu-PSMA radioligand therapy for prostate cancer

177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. The current literature suggests that this therapy is well tolerated and effective. On the basis of clinic...

Full description

Saved in:
Bibliographic Details
Main Authors: Fendler, Wolfgang (Author) , Rahbar, Kambiz (Author) , Herrmann, Ken (Author) , Kratochwil, Clemens (Author) , Eiber, Matthias (Author)
Format: Article (Journal)
Language:English
Published: August 1, 2017
In: Journal of nuclear medicine
Year: 2017, Volume: 58, Issue: 8, Pages: 1196-1200
ISSN:2159-662X
DOI:10.2967/jnumed.117.191023
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.2967/jnumed.117.191023
Verlag, kostenfrei, Volltext: https://jnm.snmjournals.org/content/58/8/1196
Get full text
Author Notes:Wolfgang P. Fendler, Kambiz Rahbar, Ken Herrmann, Clemens Kratochwil, and Matthias Eiber

MARC

LEADER 00000caa a2200000 c 4500
001 1743535937
003 DE-627
005 20230428024237.0
007 cr uuu---uuuuu
008 201223s2017 xx |||||o 00| ||eng c
024 7 |a 10.2967/jnumed.117.191023  |2 doi 
035 |a (DE-627)1743535937 
035 |a (DE-599)KXP1743535937 
035 |a (OCoLC)1341384306 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Fendler, Wolfgang  |e VerfasserIn  |0 (DE-588)1208664964  |0 (DE-627)1695018540  |4 aut 
245 1 0 |a 177Lu-PSMA radioligand therapy for prostate cancer  |c Wolfgang P. Fendler, Kambiz Rahbar, Ken Herrmann, Clemens Kratochwil, and Matthias Eiber 
246 3 0 |a one hundred and seventy-seven 
246 3 3 |a 177 Lu-PSMA radioligand therapy for prostate cancer 
264 1 |c August 1, 2017 
300 |a 5 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Die Zahl 177 ist im Titel hochgestellt 
500 |a Gesehen am 23.12.2020 
520 |a 177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. The current literature suggests that this therapy is well tolerated and effective. On the basis of clinical need and current evidence, the therapy is being implemented in a growing number of centers worldwide. Here, we review important aspects of 177Lu-PSMA RLT, including patient stratification, the therapy protocol, concomitant medication, and follow-up, to inform medical staff involved in the RLT and care of patients with metastatic castration-resistant prostate cancer. 
650 4 |a education 
650 4 |a genitourinary 
650 4 |a lutetium 
650 4 |a PSMA 
650 4 |a radionuclide therapy 
650 4 |a therapy 
700 1 |a Rahbar, Kambiz  |e VerfasserIn  |4 aut 
700 1 |a Herrmann, Ken  |e VerfasserIn  |4 aut 
700 1 |a Kratochwil, Clemens  |d 1978-  |e VerfasserIn  |0 (DE-588)134026276  |0 (DE-627)559871686  |0 (DE-576)300262787  |4 aut 
700 1 |a Eiber, Matthias  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of nuclear medicine  |d New York, NY : Soc., 1964  |g 58(2017), 8, Seite 1196-1200  |h Online-Ressource  |w (DE-627)325793603  |w (DE-600)2040222-3  |w (DE-576)09475277X  |x 2159-662X  |7 nnas  |a 177Lu-PSMA radioligand therapy for prostate cancer 
773 1 8 |g volume:58  |g year:2017  |g number:8  |g pages:1196-1200  |g extent:5  |a 177Lu-PSMA radioligand therapy for prostate cancer 
856 4 0 |u https://doi.org/10.2967/jnumed.117.191023  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://jnm.snmjournals.org/content/58/8/1196  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20201223 
993 |a Article 
994 |a 2017 
998 |g 134026276  |a Kratochwil, Clemens  |m 134026276:Kratochwil, Clemens  |d 910000  |d 911400  |e 910000PK134026276  |e 911400PK134026276  |k 0/910000/  |k 1/910000/911400/  |p 4 
999 |a KXP-PPN1743535937  |e 3828362109 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"disp":"177Lu-PSMA radioligand therapy for prostate cancerJournal of nuclear medicine","recId":"325793603","name":{"displayForm":["Society of Nuclear Medicine"]},"origin":[{"publisher":"Soc.","dateIssuedKey":"1964","dateIssuedDisp":"1964-","publisherPlace":"New York, NY"}],"id":{"eki":["325793603"],"zdb":["2040222-3"],"issn":["2159-662X","1535-5667"]},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"corporate":[{"role":"isb","display":"Society of Nuclear Medicine"}],"title":[{"title_sort":"Journal of nuclear medicine","subtitle":"JNM","title":"Journal of nuclear medicine"}],"part":{"text":"58(2017), 8, Seite 1196-1200","extent":"5","pages":"1196-1200","volume":"58","year":"2017","issue":"8"},"pubHistory":["Nachgewiesen 5.1964 -"],"titleAlt":[{"title":"JNM"}],"note":["Gesehen am 13.12.2021"]}],"titleAlt":[{"title":"177 Lu-PSMA radioligand therapy for prostate cancer"}],"note":["Die Zahl 177 ist im Titel hochgestellt","Gesehen am 23.12.2020"],"name":{"displayForm":["Wolfgang P. Fendler, Kambiz Rahbar, Ken Herrmann, Clemens Kratochwil, and Matthias Eiber"]},"recId":"1743535937","id":{"doi":["10.2967/jnumed.117.191023"],"eki":["1743535937"]},"origin":[{"dateIssuedDisp":"August 1, 2017","dateIssuedKey":"2017"}],"physDesc":[{"extent":"5 S."}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"role":"aut","given":"Wolfgang","family":"Fendler","display":"Fendler, Wolfgang"},{"family":"Rahbar","given":"Kambiz","role":"aut","display":"Rahbar, Kambiz"},{"given":"Ken","role":"aut","family":"Herrmann","display":"Herrmann, Ken"},{"display":"Kratochwil, Clemens","given":"Clemens","role":"aut","family":"Kratochwil"},{"display":"Eiber, Matthias","given":"Matthias","role":"aut","family":"Eiber"}],"title":[{"title":"177Lu-PSMA radioligand therapy for prostate cancer","title_sort":"177Lu-PSMA radioligand therapy for prostate cancer"}]} 
SRT |a FENDLERWOL177LUPSMAR1201 

Similar Items